Under clinical review. This page shows regulatory research prepared by Scriptura and is under active review by Sabrina Runbeck, PA-C, Clinical Director. Content may change on sign-off.
CJC-1295 No-DAC
Regulatory status by US jurisdiction. Reviewed and signed by a clinician. Not a dosing guide, not legal advice, and not a device.
Reviewed and signed
Clinical review: Sabrina Runbeck, PA-C, MPH, Clinical Advisor, Scriptura Health, on 2026-07-22.
Subject matter: John Edward Murray, SME, Founder and CEO, Scriptura Health, on 2026-07-22.
Verified against public sources on 2026-07-24.
Scriptura flags, alerts, and informs. The prescribing clinician makes every decision.
Federal posture
- Not FDA approved, compounding not eligible under 503A today.
- 503A bulks list: Under review by the Pharmacy Compounding Advisory Committee.
- DEA schedule: not_scheduled.
Status by jurisdiction
The verified date is the date the reviewer confirmed the status against public sources. It is not a state board confirmation. The prescribing clinician owns the compliance decision.